IGF-IR and its inhibitors in gastrointestinal carcinomas (Review)

Bao,Xiao H.; Naomoto,Yoshio; Hao,Hui F.; Watanabe,Nobuyuki; Sakurama,Kazufumi; Noma,Kazuhiro; Motoki,Takayuki; Tomono,Yasuko; Fukazawa,Takuya; Shirakawa,Yasuhiro; Yamatsuji,Tomoki; Matsuoka,Junji; Takaoka,Munenori

doi:10.3892/ol_00000036

IGF-IR and its inhibitors in gastrointestinal carcinomas (Review)

Authors:
- Xiao H. Bao
- Yoshio Naomoto
- Hui F. Hao
- Nobuyuki Watanabe
- Kazufumi Sakurama
- Kazuhiro Noma
- Takayuki Motoki
- Yasuko Tomono
- Takuya Fukazawa
- Yasuhiro Shirakawa
- Tomoki Yamatsuji
- Junji Matsuoka
- Munenori Takaoka
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000036
Pages: 195-201

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.

View Figures

View References

1	Ryan PD and Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 13:16–24. 2008. View Article : Google Scholar : PubMed/NCBI
2	Miller BS and Yee D: Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 65:10123–10127. 2005. View Article : Google Scholar : PubMed/NCBI
3	Baserga R: Oncogenes and the strategy of growth factors. Cell. 79:927–930. 1994. View Article : Google Scholar : PubMed/NCBI
4	Adachi Y, Yamamoto H, Imsumran A, et al: Insulin-like growth factor-I receptor as a candidate for a novel molecular target in the gastrointestinal cancers. Dig Endosc. 18:245–251. 2006. View Article : Google Scholar
5	Furstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol. 3:298–302. 2002. View Article : Google Scholar
6	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
7	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
8	Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D and Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 95:2086–2095. 2002. View Article : Google Scholar : PubMed/NCBI
9	Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S and Xie K: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 21:755–764. 2004. View Article : Google Scholar
10	Imsumran A, Adachi Y, Yamamoto H, et al: Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 28:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bergmann U, Funatomi H, Yokoyama M, Beger HG and Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 55:2007–2011. 1995.PubMed/NCBI
12	Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM and Li XS: Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol. 12:3977–3982. 2006.PubMed/NCBI
13	Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine. 28:20–47. 2007.PubMed/NCBI
14	Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kwon J, Stephan S, Mukhopadhyay A, Muders MH, Dutta SK, Lau JS and Mukhopadhyay D: Insulin receptor substrate-2- mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. Cancer Res. 69:1350–1357. 2009. View Article : Google Scholar
16	Almeida A, Muleris M, Dutrillaux B and Malfoy B: The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer. 11:63–65. 1994. View Article : Google Scholar : PubMed/NCBI
17	Berns EM, Klijn JG, van Staveren IL, Portengen H and Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res. 52:1036–1039. 1992.PubMed/NCBI
18	Armengol G, Knuutila S, Lluís F, Capellà G, Miró R and Caballín MR: DNA copy number changes and evaluation of MYC, IGF1R and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet. 116:133–141. 2000. View Article : Google Scholar : PubMed/NCBI
19	Natrajan R, Reis-Filho JS, Little SE, Messahel B, Brundler MA, Dome JS, Grundy PE, Vujanic GM, Pritchard-Jones K and Jones C: Blastemal expression of type I insulin-like growth factor receptor in Wilms’ tumors is driven by increased copy number and correlates with relapse. Cancer Res. 66:11148–11155. 2006.
20	Meng Z, Jackson NL, Choi H, King PH, Emanuel PD and Blume SW: Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dys-regulation of IGF-IR translational control in human breast tumor cells. J Cell Physiol. 217:172–183. 2008. View Article : Google Scholar
21	Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G and Kaaks R: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 92:1910–1917. 2000. View Article : Google Scholar : PubMed/NCBI
22	Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E and Kaaks R: Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3 and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 50:642–646. 2002. View Article : Google Scholar : PubMed/NCBI
23	Nakamura M, Miyamoto S, Maeda H, Zhang SC, Sangai T, Ishii G, Hasebe T, Endoh Y, Saito N, Asaka M and Ochiai A: Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes’ C human colorectal cancers. Clin Cancer Res. 10:8434–8441. 2004.PubMed/NCBI
24	Höpfner M, Baradari V, Huether A, Schöfl C and Scherübl H: The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer. 13:135–149. 2006.PubMed/NCBI
25	Hopfner M, Sutter AP, Huether A, Baradari V and Scherubl H: Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol. 12:5635–5643. 2006.PubMed/NCBI
26	Piao W, Wang Y, Adachi Y, et al: Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther. 7:1483–1493. 2008. View Article : Google Scholar : PubMed/NCBI
27	Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE and Ellis LM: Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 5:1676–1682. 2006. View Article : Google Scholar : PubMed/NCBI
28	Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE and Ellis LM: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth and metastasis of colon cancer. Lab Invest. 82:1377–1389. 2002. View Article : Google Scholar : PubMed/NCBI
29	Gooch JL, van Den Berg CL and Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat. 56:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
30	Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y and Beech DJ: Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res. 94:1–5. 2000. View Article : Google Scholar : PubMed/NCBI
31	Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP and Imai K: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut. 54:591–600. 2005. View Article : Google Scholar : PubMed/NCBI
32	Ullrich A, Gray A, Tam AW, et al: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5:2503–2512. 1986.
33	Hofmann F and Garcia-Echeverria C: Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today. 10:1041–1047. 2005. View Article : Google Scholar : PubMed/NCBI
34	Lee JS, Weiss J, Martin JL and Scott CD: Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer. 107:564–570. 2003. View Article : Google Scholar : PubMed/NCBI
35	Zhang X and Yee D: Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res. 62:4369–4375. 2002.PubMed/NCBI
36	Goya M, Miyamoto S, Nagai K, et al: Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 64:6252–6258. 2004. View Article : Google Scholar
37	Pollak M: Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab. 22:625–638. 2008. View Article : Google Scholar : PubMed/NCBI
38	Rodon J, DeSantos V, Ferry RJ Jr and Kurzrock R: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 7:2575–2588. 2008. View Article : Google Scholar : PubMed/NCBI
39	Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P and Gualberto A: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 26:3196–3203. 2008. View Article : Google Scholar : PubMed/NCBI
40	Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM, Green S and Gualberto A: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol. 27:2516–2522. 2009. View Article : Google Scholar
41	Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS and Moyer JD: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 11:2063–2073. 2005. View Article : Google Scholar : PubMed/NCBI
42	Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63:8912–8921. 2003.PubMed/NCBI
43	Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ and Harari PM: Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res. 67:1155–1162. 2007. View Article : Google Scholar : PubMed/NCBI
44	Wu KD, Zhou L, Burtrum D, Ludwig DL and Moore MA: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother. 56:343–357. 2007.PubMed/NCBI
45	Prewett M, Damoci C, Bassi R, Ludwig DL, Hicklin DJ and Tonra JR: IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts. Proc Am Assoc Cancer Res. 48:6522007.PubMed/NCBI
46	Tonra JR, Corcoran E, Makhoul G, et al: Synergistic anti-tumor effects of anti-EGFR monoclonal antibody Erbitux^® combined with antibodies targeting IGF1R or VEGFR-2. Proc Am Assoc Cancer Res. 46:11932005.
47	Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF and Corvaia N: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the anti-tumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 113:316–328. 2005. View Article : Google Scholar
48	Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Corvaïa N and Goetsch L: Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer. 124:2281–2293. 2009. View Article : Google Scholar : PubMed/NCBI
49	Pandini G, Wurch T, Akla B, et al: Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer. 43:1318–1327. 2007. View Article : Google Scholar
50	Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J and Goldfine ID: Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat. 94:37–46. 2005. View Article : Google Scholar : PubMed/NCBI
51	Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF and Goldfine ID: Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem. 103:624–635. 2008. View Article : Google Scholar : PubMed/NCBI
52	Rowe DL, Ozbay T, Bender LM and Nahta R: Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther. 7:1900–1908. 2008. View Article : Google Scholar : PubMed/NCBI
53	Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ and Youngren JF: A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 101:436–439. 2008. View Article : Google Scholar : PubMed/NCBI
54	Garcia-Echeverria C, Pearson MA, Marti A, et al: In vivo antitumor activity of NVP-AEW541 – a novel, potent and selective inhibitor of the IGF-IR kinase. Cancer Cell. 53:231–239. 2004.
55	Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK and Stoeltzing O: Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer. 44:1577–1586. 2008. View Article : Google Scholar
56	Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D and Scherübl H: Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Bio Chem Pharmacol. 71:1435–1448. 2006.
57	Kaulfuss S, Burfeind P, Gaedcke J and Scharf JG: Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther. 8:821–833. 2009. View Article : Google Scholar : PubMed/NCBI
58	Favelyukis S, Till JH, Hubbard SR and Miller WT: Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol. 8:1058–1063. 2001. View Article : Google Scholar : PubMed/NCBI
59	Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O and Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64:236–242. 2004. View Article : Google Scholar : PubMed/NCBI
60	Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M and Larsson O: The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene. 23:7854–7862. 2004. View Article : Google Scholar
61	Menu E, Jernberg-Wiklund H, Stromberg T, de Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K, van Camp B and Vanderkerken K: Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 107:655–660. 2006. View Article : Google Scholar : PubMed/NCBI
62	Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P and Breuhahn K: Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 48:146–156. 2008. View Article : Google Scholar : PubMed/NCBI
63	Menu E, Jernberg-Wiklund H, de Raeve H, et al: Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer. 121:1857–1861. 2007. View Article : Google Scholar
64	Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, Girnita A, Axelson M, Girnita L and Larsson O: Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene. 27:1629–1638. 2008. View Article : Google Scholar : PubMed/NCBI
65	Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, Axelson M and Girnita L: Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol. 73:930–939. 2008. View Article : Google Scholar
66	Linder S, Shoshan MC and Gupta RS: Picropodophyllotoxin or podophyllotoxin does not induce cell death via insulin-like growth factor-I receptor. Cancer Res. 67:2899–2900. 2007. View Article : Google Scholar : PubMed/NCBI